ALEMTUZUMAB+FLUDARABİN+ SİKLOFOSFAMİD PROTOKOLÜ

Kaynaklar:

1- Ngwube, A., R. J. Hayashi, L. Murray, et al. 2015. "Alemtuzumab based reduced intensity transplantation for pediatric severe aplastic anemia." Pediatr Blood Cancer 62(7):1270-1276.

2-Chakrabarti, S., I. Avivi, S. Mackinnon, et al. 2002. "Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality." Br J Haematol 119(4):1125-1132.

3-Avivi, I., S. Chakrabarti, D. W. Milligan, et al. 2004. "Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab." Biol Blood Marrow Transplant 10(3):186-194.

4-Marsh, J. C., V. Gupta, Z. Lim, et al. 2011. "Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia." Blood 118(8):2351-2357.

5-Gupta, V., S. E. Ball, D. Sage, et al. 2005. "Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning." Bone Marrow Transplant 35(5):467-471.

6- Juliusson, G., N. Theorin, K. Karlsson, et al. 2006. "Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival." Bone Marrow Transplant 37(5):503-510.